ClinicalTrials.Veeva

Menu

Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer

Lilly logo

Lilly

Status and phase

Completed
Phase 2

Conditions

Breast Cancer

Treatments

Drug: pemetrexed

Study type

Interventional

Funder types

Industry

Identifiers

NCT00065533
7491
H3E-MC-JMGE

Details and patient eligibility

About

The purposes of this study are to determine the safety of pemetrexed and any side effects that might be associated with it, whether pemetrexed can help patients with breast cancer and how much pemetrexed should be given to patients.

Enrollment

92 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Be at least 18 years of old.
  • Have been diagnosed with breast cancer
  • At least one year disease-free interval after initial treatment.
  • Have pre-study laboratory tests that are within the requirements of this study.
  • Be able to visit the doctor's office weekly during the treatment period.

Exclusion criteria

  • To be pregnant or breastfeeding.
  • To be currently taking aspirin or aspirin- like medicine and unable to stop for a few days during each cycle of therapy.
  • To have received prior chemotherapy for the treatment of metastatic cancer. Patients may have received prior hormonal treatment.
  • To have another illness that your doctor thinks would make you unable to participate.
  • To be unable or not willing to take folic acid and vitamin B12.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

19

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems